Fludarabine-based hematopoietic stem cell transplantation (HSCT) has shown to be a feasible treatment for<unk> .
Idiopathic CD4+ lymphocytopenia
Persistent polyclonal B-cell lymphocytosis
Monoclonal B-cell lymphocytosis
X-linked lymphoproliferative disease
Thymic hypoplasia
Dermatopathic lymphadenopathy
Adult-onset immunodeficiency syndrome
CD25 deficiency